Stock Market Impact: Gilead Sciences Inc. (NASDAQ:GILD) shares increased approximately 2.5% on Friday after the U.S. Food and Drug Administration approved Hepcludex (bulevirtide‑gmod) for chronic hepatitis delta virus (HDV) infection.
Listed Companies and Sectors: The approval adds the first FDA‑approved HDV therapy to Gilead’s portfolio, strengthening its position in the pharmaceuticals/biotechnology sector.
Investment Flows: No explicit measures affecting foreign direct or portfolio investment are mentioned; however, the breakthrough may attract heightened investor interest in Gilead and the antiviral drug market.
Interest Rates, Inflation, and Liquidity: The article contains no information related to monetary policy, interest rates, inflation, or liquidity conditions.
Fiscal or Monetary Policy: No fiscal or monetary policy actions are referenced.
FDA Approval Details
Drug: Hepcludex (bulevirtide‑gmod) injection, 8.5 mg administered once daily.
Indication: Treatment of chronic HDV infection in adults without cirrhosis or with compensated cirrhosis.
Regulatory Designations: Granted Breakthrough Therapy Designation, Orphan‑Drug Designation, priority review, and approved under the Accelerated Approval pathway.
Clinical Trial Results (Phase 3 MYR301)
Design: Participants randomized to immediate Hepcludex treatment for 144 weeks or delayed treatment (48‑week observation followed by 96 weeks of Hepcludex).
Primary Efficacy Endpoint (combined response at week 48): 48% in the immediate‑treatment group versus 2% in the delayed‑treatment group.
Undetectable HDV RNA Rates: 20% at week 48, 36% at week 96, and 50% at week 144 in the Hepcludex group.
Safety Profile: Reported adverse events include hypersensitivity reactions (including anaphylaxis), injection‑site reactions, headache, abdominal pain, fatigue, and pruritus. The labeling carries a boxed warning that discontinuation may lead to severe acute exacerbations of HDV and HBV infection.
